{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:37:24Z","timestamp":1765280244976,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006792","name":"Hartwell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Renal medullary carcinoma (RMC) is a rare but aggressive tumor often complicated by early lung metastasis with few treatment options and very poor outcomes. There are currently no verified RMC patient-derived xenograft (PDX) mouse models established from metastatic pleural effusion (PE) available to study RMC and evaluate new therapeutic options.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Renal tumor tissue and malignant PE cells from an RMC patient were successfully engrafted into 20 NOD.Cg-Prkdc<jats:sup>scid<\/jats:sup> Il2rg<jats:sup>tm1Wjl<\/jats:sup>\/SzJ (NSG) mice. We evaluated the histopathological similarity of the renal tumor and PE PDXs with the original patient renal tumor and PE, respectively. We then evaluated the molecular integrity of the renal tumor PDXs between passages, as well as the PE PDX compared to two generations of renal tumor PDXs, by microarray analysis. The therapeutic efficacy of sunitinib and temsirolimus was tested in a serially-transplanted generation of 27 PE PDX\u00a0mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The pathologic characteristics of the patient renal tumor and patient PE were retained in the PDXs. Gene expression profiling revealed high concordance between the two generations of renal tumor PDXs (RMC-P0 vs. RMC-P1, r=0.865), as well as between the first generation PE PDX and each generation of the renal tumor PDX (PE-P0 vs. RMC-P0, r=0.919 and PE-P0 vs. RMC-P1, r=0.843). A low number (626) of differentially-expressed genes (DEGs) was seen between the first generation PE PDX and the first generation renal tumor PDX. In the PE-P1 xenograft, sunitinib significantly reduced tumor growth (p&amp;lt;0.001) and prolonged survival (p=0.004) compared to the vehicle control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A metastatic PE-derived RMC PDX model was established and shown to maintain histologic features of the patient cancer. Molecular integrity of the PDX models was well maintained between renal tumor and PE PDX as well as between two successive renal tumor PDX generations. Using the PE PDX model, sunitinib demonstrated therapeutic efficacy for RMC. This model can serve as a foundation for future mechanistic and therapeutic studies for primary and metastatic RMC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.648097","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T05:50:19Z","timestamp":1616737819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib"],"prefix":"10.3389","volume":"11","author":[{"given":"Alex Q.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Ijiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Gandour-Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford G.","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kit","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-199501000-00001","article-title":"Renal medullary carcinoma. The seventh sickle cell nephropathy","volume":"19","author":"Davis","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26609","article-title":"Renal medullary carcinoma: A national analysis of 159 patients","volume":"64","author":"Ezekian","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11934-019-0865-9","article-title":"Renal Medullary Carcinoma: a Report of the Current Literature","volume":"20","author":"Blas","year":"2019","journal-title":"Curr Urol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25592","article-title":"Renal medullary carcinoma and sickle cell trait: A systematic review","volume":"62","author":"Alvarez","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<128::AID-CNCR18>3.0.CO;2-1","article-title":"Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor","volume":"78","author":"Avery","year":"1996","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02154-4","article-title":"Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications","volume":"60","author":"Swartz","year":"2002","journal-title":"Urology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.020909","article-title":"Renal Medullary Carcinoma: Establishing Standards in Practice","volume":"13","author":"Beckermann","year":"2017","journal-title":"J Oncol Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13705","article-title":"Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study","volume":"120","author":"Shah","year":"2017","journal-title":"BJU Int"},{"article-title":"Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.)","volume-title":"Guide for the care and use of laboratory animals","year":"2011","key":"B9"},{"key":"B10","first-page":"379","volume-title":"Analysis of longitudinal data","author":"Diggle","year":"2013"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1200\/JCO.2005.05.0344","article-title":"Medullary renal cell carcinoma and response to therapy with bortezomib","volume":"24","author":"Ronnen","year":"2006","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.155","article-title":"Phase II trial of bortezomib for patients with advanced renal cell carcinoma","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20292","article-title":"Significant responses to platinum-based chemotherapy in renal medullary carcinoma","volume":"44","author":"Strouse","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/01.coc.0000037663.61643.5A","article-title":"Renal medullary carcinoma: case report and review of the literature","volume":"26","author":"Noguera-Irizarry","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199901000-00015","article-title":"Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma","volume":"21","author":"Pirich","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.05.009","article-title":"High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review","volume":"72","author":"Rathmell","year":"2008","journal-title":"Urology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.2.283","article-title":"mTOR pathway in renal cell carcinoma","volume":"8","author":"Hanna","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1200\/jco.2007.25.18_suppl.5010","article-title":"Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis","volume":"25","author":"Gore","year":"2007","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60327-149-3_32","article-title":"Management of Patients with Pathologic Variants of Renal Cell Carcinoma: Papillary, Collecting Duct, Medullary and Chromophobe Carcinoma, and Sarcomatoid Differentiation","volume-title":"Clinical Management of Renal Tumors","author":"Hugec","year":"2008"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20049","article-title":"Gene expression profiling of renal medullary carcinoma: potential clinical relevance","volume":"100","author":"Yang","year":"2004","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100745","DOI":"10.1016\/j.tranon.2020.100745","article-title":"Choosing The Right Animal Model for Renal Cancer Research","volume":"13","author":"Sobczuk","year":"2020","journal-title":"Transl Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10659","article-title":"Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma","volume":"7","author":"Lang","year":"2016","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ccell.2020.04.002","article-title":"Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma","volume":"37","author":"Msaouel","year":"2020","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41419-018-0865-6","article-title":"A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma","volume":"9","author":"Einarsdottir","year":"2018","journal-title":"Cell Death Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40880-018-0284-1","article-title":"Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance","volume":"38","author":"Xu","year":"2018","journal-title":"Cancer Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0602-z","article-title":"Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model","volume":"122","author":"Iankov","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B29","article-title":"Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers","volume":"9","author":"Verschraegen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B30","article-title":"Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts","volume":"62","author":"Rofstad","year":"2002","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/dc.21111","article-title":"Cytology of metastatic renal medullary carcinoma in pleural effusion: a study of two cases","volume":"37","author":"Ellis","year":"2009","journal-title":"Diagn Cytopathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22611","article-title":"Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma","volume":"55","author":"Walsh","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"129813","DOI":"10.1155\/2013\/129813","article-title":"Renal medullary cancer in a patient with sickle cell trait","volume":"2013","author":"Alappan","year":"2013","journal-title":"Case Rep Oncol Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e5981","DOI":"10.7717\/peerj.5981","article-title":"A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine","volume":"6","author":"Collins","year":"2018","journal-title":"PeerJ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"Eur Urol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"B37","article-title":"Renal medullary carcinoma: a case report and brief review of the literature","volume":"14","author":"Shetty","year":"2014","journal-title":"Ochsner J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0771","article-title":"Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy","volume":"12","author":"Arumugam","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30472","article-title":"Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors","volume":"140","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0273-1","article-title":"Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases","volume":"32","author":"Jia","year":"2019","journal-title":"Mod Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.04.012","article-title":"Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes","volume":"15","author":"Carlo","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.09.027","article-title":"Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas","volume":"69","author":"Calderaro","year":"2016","journal-title":"Eur Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.648097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T05:50:31Z","timestamp":1616737831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.648097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":42,"alternative-id":["10.3389\/fonc.2021.648097"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.648097","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"article-number":"648097"}}